Acquired by Lundbeck
Industries BiotechnologyHealth CarePharmaceuticalHeadquarters Regions East Coast, Southern US Closed Date 2014 Founded Date 2004 Founders Simon Pedder Operating Status Closed Last Funding Type Post-IPO Equity
Stock Symbol NASDAQ:CHTP Company Type For Profit
Contact Email webemail06@chelseatherapeutics.com Phone Number (704) 341-1516
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions
and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.
Transaction Name Chelsea Therapeutics International acquired by LundbeckAcquired by LundbeckAnnounced Date May 8, 2014 Price $658M